K36 Therapeutics, Inc.
Clinical trials sponsored by K36 Therapeutics, Inc., explained in plain language.
-
New pill shows promise for Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-stage trial tests a new daily pill, KTX-1001, for people with multiple myeloma that has returned or stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors or slow the cancer. About 125 adults who have tried at l…
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:39 UTC
-
New drug combo targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see if it helps control the can…
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:30 UTC